Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

CYTOKINETICS, INC. (CYTK)
Mes dernières consult.
Most popular
Report
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/19/2011 | 02:40pm CET
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
01/03 CYTOKINETICS INC : Other Events (form 8-K)
01/03 Cytokinetics Announces Progress Against Vision 2020
2017 CYTOKINETICS : Suffers over Missing Endpoints
2017 CYTOKINETICS INC : Other Events (form 8-K)
2017 Cytokinetics Announces Presentation of Results From VITALITY-ALS at 28th Inte..
2017 CYTOKINETICS : Investigational ALS Drug Fails in Phase 3 Clinical Trial
2017 Cytokinetics Announces Results of VITALITY-ALS to be Presented at the Interna..
2017 Investor Expectations to Drive Momentum within CatchMark Timber Trust, Global..
2017 CYTOKINETICS : New Publication Shows Respiratory Decline Correlated With Disease..
2017 CYTOKINETICS : New Publication Summarizes Phase 1 Studies of CK-2127107 Showing ..
More news
Financials ($)
Sales 2017 19,7 M
EBIT 2017 -111 M
Net income 2017 -120 M
Finance 2017 181 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 18,3x
EV / Sales 2018 13,4x
Capitalization 542 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 15,1 $
Spread / Average Target 50%
EPS Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Ching Jaw Chief Financial Officer & Senior Vice President
Andrew A. Wolff Chief Medical Officer & Senior Vice President
Fady Ibraham Malik Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.542
GILEAD SCIENCES13.04%106 315
VERTEX PHARMACEUTICALS5.41%40 948
REGENERON PHARMACEUTICALS-1.18%40 382
GENMAB13.75%11 797
BIOVERATIV INC92.49%11 230